Viracta Therapeutics (VIRX) Competitors $0.02 +0.00 (+10.00%) As of 02:31 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock VIRX vs. PTN, AWH, TNFA, GLMD, PTIX, ENTO, APVO, GRTX, SHPH, and VCNXShould you be buying Viracta Therapeutics stock or one of its competitors? The main competitors of Viracta Therapeutics include Palatin Technologies (PTN), Aspira Women's Health (AWH), TNF Pharmaceuticals (TNFA), Galmed Pharmaceuticals (GLMD), Protagenic Therapeutics (PTIX), Entero Therapeutics (ENTO), Aptevo Therapeutics (APVO), Galera Therapeutics (GRTX), Shuttle Pharmaceuticals (SHPH), and Vaccinex (VCNX). These companies are all part of the "pharmaceutical products" industry. Viracta Therapeutics vs. Its Competitors Palatin Technologies Aspira Women's Health TNF Pharmaceuticals Galmed Pharmaceuticals Protagenic Therapeutics Entero Therapeutics Aptevo Therapeutics Galera Therapeutics Shuttle Pharmaceuticals Vaccinex Palatin Technologies (NYSE:PTN) and Viracta Therapeutics (NASDAQ:VIRX) are both small-cap manufacturing companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, earnings, valuation, risk, community ranking, dividends, analyst recommendations, institutional ownership and media sentiment. Does the MarketBeat Community prefer PTN or VIRX? Viracta Therapeutics received 29 more outperform votes than Palatin Technologies when rated by MarketBeat users. Likewise, 70.73% of users gave Viracta Therapeutics an outperform vote while only 0.00% of users gave Palatin Technologies an outperform vote. CompanyUnderperformOutperformPalatin TechnologiesOutperform VotesNo VotesUnderperform Votes5100.00% Viracta TherapeuticsOutperform Votes2970.73% Underperform Votes1229.27% Do institutionals & insiders have more ownership in PTN or VIRX? 11.5% of Palatin Technologies shares are held by institutional investors. Comparatively, 31.4% of Viracta Therapeutics shares are held by institutional investors. 7.1% of Palatin Technologies shares are held by company insiders. Comparatively, 10.7% of Viracta Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Do analysts recommend PTN or VIRX? Viracta Therapeutics has a consensus target price of $1.75, suggesting a potential upside of 9,258.29%. Given Viracta Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Viracta Therapeutics is more favorable than Palatin Technologies.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Palatin Technologies 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Viracta Therapeutics 0 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.33 Is PTN or VIRX more profitable? Palatin Technologies' return on equity of 0.00% beat Viracta Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Palatin TechnologiesN/A N/A N/A Viracta Therapeutics N/A -1,899.61%-114.21% Does the media favor PTN or VIRX? In the previous week, Palatin Technologies' average media sentiment score of 0.00 equaled Viracta Therapeutics'average media sentiment score. Company Overall Sentiment Palatin Technologies Neutral Viracta Therapeutics Neutral Which has more volatility and risk, PTN or VIRX? Palatin Technologies has a beta of 0.94, indicating that its stock price is 6% less volatile than the S&P 500. Comparatively, Viracta Therapeutics has a beta of 1.07, indicating that its stock price is 7% more volatile than the S&P 500. Which has stronger earnings and valuation, PTN or VIRX? Palatin Technologies has higher revenue and earnings than Viracta Therapeutics. Palatin Technologies is trading at a lower price-to-earnings ratio than Viracta Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPalatin Technologies$350K6.99-$40.31M-$1.55-0.06Viracta TherapeuticsN/AN/A-$51.06M-$1.10-0.02 SummaryViracta Therapeutics beats Palatin Technologies on 10 of the 14 factors compared between the two stocks. Get Viracta Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for VIRX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VIRX vs. The Competition Export to ExcelMetricViracta TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$743,000.00$6.84B$5.57B$8.60BDividend YieldN/A2.49%5.27%4.19%P/E Ratio-0.028.7927.2720.06Price / SalesN/A255.05409.23156.87Price / CashN/A65.8538.2534.64Price / Book0.066.557.064.70Net Income-$51.06M$143.71M$3.23B$247.80M7 Day PerformanceN/A3.76%2.69%2.17%1 Month PerformanceN/A13.97%12.06%9.41%1 Year PerformanceN/A4.76%31.40%14.73% Viracta Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VIRXViracta Therapeutics1.4029 of 5 stars$0.02+10.0%$1.75+9,258.3%-97.1%$743KN/A-0.0220Gap DownPTNPalatin TechnologiesN/A$0.09-44.6%N/AN/A$2.45M$350K-0.0630Gap DownHigh Trading VolumeAWHAspira Women's Health1.1092 of 5 stars$0.08-12.5%$5.50+6,607.3%-96.0%$2.44M$9.18M-0.07110High Trading VolumeTNFATNF PharmaceuticalsN/A$0.17+6.6%N/AN/A$2.43MN/A-0.036Gap DownHigh Trading VolumeGLMDGalmed Pharmaceuticals1.0749 of 5 stars$1.45+1.4%N/A-62.5%$2.40MN/A-0.0920PTIXProtagenic Therapeutics1.3692 of 5 stars$3.80-1.3%N/A-73.8%$2.24MN/A-2.992Short Interest ↓ENTOEntero Therapeutics0.4257 of 5 stars$0.44+1.5%N/A-75.1%$2.10MN/A0.009Short Interest ↑Gap UpAPVOAptevo Therapeutics3.2528 of 5 stars$4.77+1.1%$219,040.00+4,591,933.5%-100.0%$1.93M$3.11M0.0050Short Interest ↓Gap UpHigh Trading VolumeGRTXGalera TherapeuticsN/A$0.03+2.0%N/A-76.0%$1.92MN/A-0.0730SHPHShuttle Pharmaceuticals0.9127 of 5 stars$0.17-0.9%N/AN/A$1.90MN/A-0.045Short Interest ↓VCNXVaccinex0.3598 of 5 stars$0.72-22.1%N/A-87.5%$1.87M$388K-0.0140Gap Down Related Companies and Tools Related Companies PTN Alternatives AWH Alternatives TNFA Alternatives GLMD Alternatives PTIX Alternatives ENTO Alternatives APVO Alternatives GRTX Alternatives SHPH Alternatives VCNX Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:VIRX) was last updated on 6/11/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredHere’s How to Claim Your Stake in Elon’s Private Company, xAIEven though xAI is a private company, tech legend and angel investor Jeff Brown found a way for everyday folks...Brownstone Research | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Viracta Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Viracta Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
